Australian Meningococcal Surveillance Programme annual report, 2019
DOI:
https://doi.org/10.33321/cdi.2020.44.62Keywords:
antibiotic resistance, disease surveillance, meningococcal disease, Neisseria meningitidisAbstract
Invasive meningococcal disease (IMD) is a notifiable disease in Australia, and both probable and laboratory-confirmed cases of IMD are reported to the National Notifiable Diseases Surveillance System (NNDSS). In 2019, there were 206 notifications of IMD. Of these, 202 were laboratory-confirmed cases analysed by the reference laboratories of the Australian National Neisseria Network (NNN). Of the 202 laboratory-confirmed cases of IMD, 167 were confirmed by bacterial culture and 35 by nucleic acid amplification testing, and all had the serogroup determined. Fine typing was available on 146 samples (146/202, 72%). Neisseria meningitidis serogroup B (MenB) infections accounted for 50.0% (101/202); MenW for 26.2% (53/202); MenY for 20.8% (42/202) and MenC for 3.0% of cases (6/202). Of the MenW cases, 88% were PorA antigen type P1.5,2, and 65% of these (24/37) were sequence type 11, the hypervirulent strain reported in recent outbreaks in Australia and overseas.
The primary peaks of IMD notifications in Australia in 2019 were observed in infants less than 1 year of age (36/202, 18%) and in adults aged 65 years or older (39/202, 19%). MenB infections predominated in those aged less than 5 years and those aged 15–19 years, whereas MenW and MenY infections predominated in those aged 45 years or more.
All 167 IMD isolates were tested for antimicrobial susceptibility. One isolate out of these 167 (0.6%) was resistant to penicillin with an MIC ≥ 1mg/L; 154/167 isolates (92%) had decreased susceptibility to penicillin. All isolates were susceptible to ceftriaxone and ciprofloxacin, and one isolate was resistant to rifampicin.
Downloads
References
National Neisseria Network. Meningococcal isolate surveillance Australia 1994. Commun Dis Intell. 1995;19:286–9.
Australian Government Department of Health. National Notifiable Disease Surveillance System. [Internet.] Canberra: Australian Government Department of Health; 2019. Available from: http://www9.health.gov.au/cda/source/cda-index.cfm .
National Notifiable Diseases Surveillance System (NNDSS). Number of notifications of Meningococcal disease (invasive), received from state and territory health authorities in the period of 1991 to 2012 and year-to-date notifications for 2014. [Internet.] Canberra: Australian Government Department of Health; 2014.
Australian Government Department of Health. Invasive meningococcal disease. [Internet.] Canberra: Australian Government Department of Health; 2019. Available from: https://www.health.gov.au/internet/main/publishing.nsf/Content/ohp-meningococcal-W.htm .
Communicable Diseases Network Australia (CDNA). Invasive meningococcal disease: CDNA national guidelines for public health units. [Internet.] Canberra: Australian Government Department of Health; 2015. Available from: http://www.health.gov.au/internet/main/publishing.nsf/content/cdna-song-imd.htm .
Abad R, López EL, Debbag R, Vázquez JA. Serogroup W meningococcal disease: global spread and current affect on the Southern Cone in Latin America. Epidemiol Infect. 2014;142(12):2461–70.
Ladhani SN, Beebeejaun K, Lucidarme J, Campbell H, Gray S, Kaczmarski E. Increase in endemic Neisseria meningitidis capsular group W sequence type 11 complex associated with severe invasive disease in England and Wales. Clin Infect Dis. 2015;60(4):578–85.
Chiu C, Dey A, Wang H, Menzies R, Deeks S, Mahajan D et al. Vaccine preventable diseases in Australia, 2005 to 2007. Commun Dis Intell Q Rep. 2010;34(Suppl):S1–167.
Australian Government Department of Health. Australian Immunisation Handbook: Meningococcal disease. [Internet.] Canberra: Australian Government Department of Health; 2015. Available from: http://www.health.gov.au/internet/immunise/publishing.nsf/Content/immunise-meningococcal
Araya P, Fernández J, Del Canto F, Seoane M, Ibarz-Pavón AB, Barra G et al. Neisseria meningitidis ST-11 clonal complex Chile, 2012. Emerg Infect Dis. 2015;21(2):339–41.
Bröker M, Jacobsson S, Kuusi M, Pace D, Simões MJ, Skoczynska A et al. Meningococcal serogroup Y emergence in Europe: update 2011. Hum Vaccin Immunother. 2012;8(12):1907–11.
Published
How to Cite
License
Copyright (c) 2023 Communicable Diseases Intelligence
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
